Display options
Cite
Gessi S, Bencivenni S, Battistello E, et al. Inhibition of A. Front Pharmacol. 2017;8:888doi: 10.3389/fphar.2017.00888.
Gessi, S., Bencivenni, S., Battistello, E., Vincenzi, F., Colotta, V., Catarzi, D., Varano, F., Merighi, S., Borea, P. A., & Varani, K. (2017). Inhibition of A. Frontiers in pharmacology, 8888. https://doi.org/10.3389/fphar.2017.00888
Gessi, Stefania, et al. "Inhibition of A." Frontiers in pharmacology vol. 8 (2017): 888. doi: https://doi.org/10.3389/fphar.2017.00888
Gessi S, Bencivenni S, Battistello E, Vincenzi F, Colotta V, Catarzi D, Varano F, Merighi S, Borea PA, Varani K. Inhibition of A. Front Pharmacol. 2017 Dec 01;8:888. doi: 10.3389/fphar.2017.00888. eCollection 2017. PMID: 29249971; PMCID: PMC5716981.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2017 Dec 01;8:888. doi: 10.3389/fphar.2017.00888. eCollection 2017.

Inhibition of A.

Frontiers in pharmacology

Stefania Gessi, Serena Bencivenni, Enrica Battistello, Fabrizio Vincenzi, Vittoria Colotta, Daniela Catarzi, Flavia Varano, Stefania Merighi, Pier Andrea Borea, Katia Varani

Affiliations

  1. Department of Medical Sciences, Pharmacology Section, University of Ferrara, Ferrara, Italy.
  2. Department of Neuroscience, Psychology, Drug Research and Child Health, Pharmaceutical and Nutraceutical Section, University of Florence, Florence, Italy.

PMID: 29249971 PMCID: PMC5716981 DOI: 10.3389/fphar.2017.00888

Abstract

Several evidences indicate that the ubiquitous nucleoside adenosine, acting through A

Keywords: A2A adenosine receptor; Drug Discovery and Therapy; cancer cell proliferation; intracellular signaling pathways; receptor antagonist

References

  1. Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7 - PubMed
  2. FASEB J. 2016 Jan;30(1):457-65 - PubMed
  3. PLoS One. 2016 Mar 10;11(3):e0151420 - PubMed
  4. Pharmacol Rev. 2011 Mar;63(1):1-34 - PubMed
  5. J Cell Physiol. 2007 Jun;211(3):826-36 - PubMed
  6. J Invest Dermatol. 2002 Oct;119(4):923-33 - PubMed
  7. Br J Pharmacol. 2017 Jul;174(13):1945-1960 - PubMed
  8. Pharmacol Ther. 2003 Oct;100(1):31-48 - PubMed
  9. Cancer Biol Ther. 2013 Sep;14(9):860-8 - PubMed
  10. Trends Mol Med. 2013 Jun;19(6):355-67 - PubMed
  11. Trends Pharmacol Sci. 2016 Jun;37(6):419-34 - PubMed
  12. Nat Rev Cancer. 2013 Dec;13(12):842-57 - PubMed
  13. Oncol Rep. 2009 Apr;21(4):977-81 - PubMed
  14. Anal Biochem. 1980 Sep 1;107(1):220-39 - PubMed
  15. J Med Chem. 2016 Dec 8;59(23 ):10564-10576 - PubMed
  16. Oncoimmunology. 2016 Jul 29;5(9):e1216292 - PubMed
  17. Chem Rev. 2017 Jan 11;117(1):21-37 - PubMed
  18. Mol Pharmacol. 2000 Sep;58(3):477-82 - PubMed
  19. Biochim Biophys Acta. 2011 May;1808(5):1400-12 - PubMed
  20. Clin Cancer Res. 2008 Oct 1;14 (19):5947-52 - PubMed
  21. Cancer Res. 1997 Jul 1;57(13):2602-5 - PubMed
  22. Cancer Cell. 2016 Sep 12;30(3):391-403 - PubMed
  23. Anal Biochem. 1976 May 7;72:248-54 - PubMed
  24. Expert Rev Clin Immunol. 2014 Jul;10(7):897-914 - PubMed
  25. Med Res Rev. 2015 Jul;35(4):790-848 - PubMed
  26. Oncologist. 2013;18(1):25-6 - PubMed
  27. Med Res Rev. 2017 Jul 6;:null - PubMed

Publication Types